New hope for HS sufferers: LAD191 enters Mid-Stage trial

NCT ID NCT07151937

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new injectable drug called LAD191 in 200 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and scarring. Participants will receive either LAD191, a placebo, or an active comparator (adalimumab) to see if LAD191 reduces skin lesions by at least 50% over 16 weeks. The goal is to find a more effective treatment for HS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
LAD191 (injected under the skin)
What this could lead to
If successful, LAD191 could offer a new treatment option to reduce painful abscesses and nodules in people with hidradenitis suppurativa.
What could go wrong
This is an early Phase 2 study with only 200 participants. The drug may not work better than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital de Manises

    RECRUITING

    Manises, 46940, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.